Boston Scientific Corp (BSX) said it has received 510(k) clearance from the U.S. Food and Drug Administration and CE Mark approval to market its WallFlex Fully Covered Esophageal Stent for the treatment of malignant esophageal strictures caused by tumors in patients with resectable or non-resectable esophageal cancer.
The WallFlex Partially Covered Esophageal Stent was cleared by the FDA and received CE Mark in 2008.
For comments and feedback: editorial@rttnews.com